| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-20 | Pande Atul | director | Option exercise | 6,000 | $8.43 | $51K |
| 2026-05-20 | Pande Atul | director | Sale | 6,000 | $32.00 | $192K |
| 2026-05-01 | Susman Robert Graham | director | Sale | 2,502 | $27.17 | $68K |
| 2026-04-23 | Girao Tiago | officer | Sale | 25,760 | $29.62 | $763K |
| 2026-04-23 | Stout Jay S | officer | Sale | 2,754 | $29.62 | $82K |
| 2026-04-08 | Van Tuyl Christopher | officer | Sale | 5,165 | $24.83 | $128K |
| 2026-04-08 | Gloria Melanie | officer | Sale | 8,722 | $24.83 | $217K |
| 2026-04-08 | Stout Jay S | officer | Sale | 8,614 | $24.83 | $214K |
| 2026-04-08 | Stout Jay S | officer | Sale | 1,518 | $24.83 | $38K |
| 2026-04-07 | Torti Frank | director | Award | 174,189 | — | — |
| 2026-04-07 | Fromkin Andrew J. | director | Award | 13,880 | — | — |
| 2026-04-07 | Hughes Douglas J. | director | Award | 13,880 | — | — |
| 2026-04-07 | Pande Atul | director | Award | 13,880 | — | — |
| 2026-04-07 | Bauer Jake | director | Award | 13,880 | — | — |
| 2026-04-07 | Susman Robert Graham | director | Award | 13,880 | — | — |
| 2026-04-07 | Gloria Melanie | officer | Award | 83,671 | — | — |
| 2026-04-07 | Stout Jay S | officer | Award | 66,937 | — | — |
| 2026-04-07 | Van Tuyl Christopher | officer | Award | 41,343 | — | — |
| 2026-04-07 | Venker Eric | director, officer | Award | 232,252 | — | — |
| 2026-04-07 | Girao Tiago | officer | Award | 64,968 | — | — |
| 2026-04-07 | Girao Tiago | officer | Award | 94,002 | $24.61 | $2.31M |
| 2026-04-07 | Venker Eric | director, officer | Award | 336,043 | $24.61 | $8.27M |
| 2026-04-07 | Van Tuyl Christopher | officer | Award | 59,820 | $24.61 | $1.47M |
| 2026-04-07 | Stout Jay S | officer | Award | 96,851 | $24.61 | $2.38M |
| 2026-04-07 | Gloria Melanie | officer | Award | 121,063 | $24.61 | $2.98M |
| Filed | Form | Filer | Stake | Shares | |
|---|---|---|---|---|---|
| 2025-01-15 | SCHEDULE | Roivant Sciences Ltd. | 56.90% | 96,660,341 | view → |
| 2023-10-04 | SC | Roivant Sciences Ltd. | — | — | view → |
| 2021-08-02 | SC | Roivant Sciences Ltd. | — | — | view → |
| 2021-03-08 | SC | Roivant Sciences Ltd. | — | — | view → |
| 2020-09-04 | SC | Roivant Sciences Ltd. | — | — | view → |
| Filed | Form | Issuer | Stake | Shares | |
|---|---|---|---|---|---|
| 2026-10-05 | SCHEDULE 13D/A | Arbutus Biopharma Corp | 19.50% | 29,880,079 | view → |
| 2025-02-25 | SCHEDULE | Arbutus Biopharma Corp ABUS | 20.50% | 38,847,462 | view → |
| 2025-02-18 | SCHEDULE | Arbutus Biopharma Corp ABUS | 20.50% | 38,847,462 | view → |
| 2025-01-15 | SCHEDULE | Immunovant, Inc. IMVT | 56.90% | 96,660,341 | view → |
| 2023-10-04 | SC | Immunovant, Inc. IMVT | — | — | view → |
| 2021-10-20 | SC | Arbutus Biopharma Corp ABUS | — | — | view → |
| 2021-08-02 | SC | Immunovant, Inc. IMVT | — | — | view → |
| 2021-03-08 | SC | Immunovant, Inc. IMVT | — | — | view → |
| 2020-09-04 | SC | Immunovant, Inc. IMVT | — | — | view → |
| 2019-12-31 | SC | Urovant Sciences Ltd. | — | — | view → |
| 2019-12-31 | SC | Axovant Gene Therapies Ltd. | — | — | view → |
| 2019-12-31 | SC | Myovant Sciences Ltd. | — | — | view → |
| 2019-07-16 | SC | Urovant Sciences Ltd. | — | — | view → |
| 2019-07-16 | SC | Arbutus Biopharma Corp ABUS | — | — | view → |
| 2019-07-16 | SC | Myovant Sciences Ltd. | — | — | view → |
| 2019-07-16 | SC | Axovant Gene Therapies Ltd. | — | — | view → |
| 2019-03-19 | SC | Axovant Sciences Ltd. | — | — | view → |
| 2018-04-23 | SC | Arbutus Biopharma Corp ABUS | — | — | view → |
| 2018-04-12 | SC | Arbutus Biopharma Corp ABUS | — | — | view → |
| 2018-03-16 | SC | Arbutus Biopharma Corp ABUS | — | — | view → |
Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.
See pricing →